The role of superantigens in vasculitis

Current Opinion in Rheumatology

Volumn 11, Issue 1, 1999, Pages 24-33

  Cohen Tervaert, Jan Willem ^a   Popa, Eliane R ^a   Bos, Nico A ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CELL ANTIBODY; NEUTROPHIL CYTOPLASMIC ANTIBODY; SUPERANTIGEN; T LYMPHOCYTE RECEPTOR;

B LYMPHOCYTE; BLOOD VESSEL WALL; DISEASE PREDISPOSITION; ENDOTHELIUM CELL; ENVIRONMENTAL FACTOR; HUMAN; INFECTION; MUCOCUTANEOUS LYMPH NODE SYNDROME; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; VASCULITIS; WEGENER GRANULOMATOSIS;

EID: 0347875148     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002281-199901000-00005     Document Type: Review

References (92)

1. Somer T, Finegold SM: Vasculitides associated with infections, immunization, and antimicrobial drugs Clin Infect Dis 1995, 20:1010-1036.
2. Mandell BF, Calabrese LH: Infections and systemic vasculitis. Curr Opin Rheumatol 1998, 10:51-57.
3. Merkel PA: Drugs associated with vasculitis Curr Opin Rheumatol 1998, 10:45-50.
4. Cohen Tervaert JW, Stegeman CA, Kallenberg CGM. Silicon exposure and vasculitis. Curr Opin Rheumatol 1998, 10:12-17.
5. Kotb M: Short analytical review, infection and autoimmunity: a story of the host, the pathogen, and the copathogen. Clin Immunol Immunopathol 1995, 74:10-22.
6. Cohen IR: Autoimmunity to chaperonins in the pathogenesis of arthritis and diabetes. Annu Rev Immunol 1991, 9:567-589.
7. Dziarski R: Preferential induction of autoantibody secretion in polyclonal activation by peptidoglycan and lipopolysaccharide: I, in vitro studies. J Immunol 1982, 128:1018-1025.
8. Dziarski R: Preferential induction of autoantibody secretion in polyclonal activation by peptidoglycan and lipopolysaccharide: II. in vitro studies. J Immunol 1982, 128:1026-1030.
9. Krieg AM, Yi AK, Matson S, Waldschmidt TJ, Bishop GA, Teasdale R, et al: CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 1995, 374:546-549.
10. Friedman M, Tumang JR, Crow MK: Microbial superantigens as etiopathogenic agents in autoimmunity Rheum Dis Clin North Am 1993, 19:207-222.
11. Kotzin BL, Leung DYM, Kappler J, Marrack P: Superantigens and their potential role in human disease. Adv Immunol 1993, 54:99-166.
12. Silverman GJ: B cell superantigens: possible roles in immunodeficiency • and autoimmunity. Semin Immunol 1998, 10:43-45. This is a concise review of evidence that B-cell SAgs activate B cells with a speculation how B-cell SAgs may contribute to the development of autoimmune and immunodeficiency diseases.
13. White J, Herman A, Pullen AM, Kubo R, Kappler JW, Marrack P: The Vβ-specific superantigen staphylocaccal enterotoxin B: stimulation of mature T cells and clonal deletion in neonatal mice. Cell 1989, 56:27-35.
14. McCormack JE, Callahan JE, Kappler J, Marrack PC: Profound deletion of mature T cells in vivo by chronic exposure to exogenous superantigen. J Immunol 1993, 150:3785-3792
15. Dellabona P, Peccoud J, Kappler J, Marrack P, Benoist C, Mathis D: Superantigens interact with MHC class II molecules outside the antigen groove. Cell 1990, 62:1115-1121
16. Musser JM: Streptococcal superantigen, mitogenic factor, and pyrogenic exotoxin B expressed by Streptococcus pyogenes: structure and function. In Superantigens: Molecular Biology, Immunology, and Relevance to Human Disease. Edited by Leung DYM. Huber BT, Sohlievert PM. New York: Marcel Dekker; 1997:281-310.
17. Kotb M Streptococcal M protein: role in post-streptococcal autoimmunity. In Superantigens: Molecular Biology, Immunology, and Relevance to Human Disease. Edited by Leung DYM, Huber BT, Schlievert PM. New York: Marcel Dekker; 1997:311-338.
18. Maillard I, Luthi F, Acha-Orbea H, Diggelmann H: Role of the immune response induced by superantigens in the pathogenesis of microbial infections. Parasitology 1997, 115:S67-S78.
19. Abe J, Takeda T: Characterization of a superantigen produced by Yersinia pseudotuberculosis. In Superantigens: Molecular Biology, Immunology, and Relevance to Human Disease. Edited by Leung DYM, Huber BT, Schlievert PM. New York: Marcel Dekker; 1997:369-404.
20. Ohmen JD, Modlin RL: Evidence for a superantigen in the pathogenesis of tuberculosis. Springer Semin Immunopathol 1996, 17:375-384.
21. + lymphocytes. J Exp Med 1994, 180:985-994.
22. Lafon M, Lafage M, Martinez-Arends A, Ramirez R, Vuiller F, Charron D, et al: Evidence for a viral superantigen in humans. Nature 1992, 358:507-510.
23. Sutkowski N, Palkama T, Ciurli C, Sekaly RP, Thorley-Lawson DA, Huber BT: An Epstein-Barr virus-associated superantigen. J Exp Med 1996, 184:971-980.
24. Dobrescue D, Ursea B, Pope M, Asch AS, Posnett DN: Enhanced HIV-1 replication in Vβ12 T cells due to human cytomegalovirus in monocytes: evidence for a putative herpes superantigen. Cell 1995, 82:753-763.
25. Schiffenbauer J, Soos J, Johnson H: The possible role of bacterial superantigens in the pathogenesis of autoimmune disorders. Immunol Today 1998, 19:117-120.
26. Savage COS, Harper L, Adu D: Primary systemic vasculitis. Lancet 1997, • 349:553-558. This article reviews clinical features, laboratory abnormalities, pathology and therapy, and pathophysiology of ANCA-associated vasculitis.
27. Heeringa P, Brouwer E, Cohen Tervaert JW, Weening JJ, Kallenberg CGM: • Animal models of antineutrophil cytoplasmic autoantibody-associated vasculitis. Kidney Int 1998, 53:253-263. This is a well-referenced review on the pathophysiology of ANCA-associated vasculitis with special attention to animal models.
28. Belizna C, Cohen Tervaert JW: Specif city, pathogenecity, and clinical value • of antiendothelial cell antibodies. Semin Arthritis Rheum 1997, 27:98-109. This article reviews the putative target antigens for AECA, the possible pathophysiologic role, and the clinical value of these antibodies as markers of disease activity.
29. Tumang JR, Cherniack EP, Gietl DM, Cole BC, Russo C, Crow MK, Friedman M: T helper cell-dependent, microbial superantigen-induced murine B cell activation: polyclonal and antigen-specific antibody responses. J Immunol 1991, 147:432-438.
30. Florquin S, Amraoui Z, Goldman M: Persistent production of TH-2 type cytokines and polyclonal B cell activation after chronic administration of staphylococcal enterotoxin B in mice. J Autoimmun 1996, 9:609-615.
31. Tumang JR, Zhou JL, Gietl D, Crow MK, Elkon K, Friedman SM: T helper cell-dependent, microbial superantigen-mediated B cell activation in vivo. Autoimmunity 1996, 24:247-255.
32. + cells in the kidney. J Am Soc Nephrol 1996, 7:1744.
33. Abe Y, Nakano S, Aita K, Sagishima M: Streptococcal and staphylococcal superantigen-induced lymphocyte arteritis in a local type experimental model: comparison with acute vasculitis in the Arthus reaction. J Lab Clin Med 1998, 131:93-102.
34. +-dependent binding.
35. Fink CW: The role of the streptococcus in poststreptococcal reactive arthritis and childhood polyarteritis nodosa. J Rheumatol 1991 18(suppl 29):14-20.
36. Ekman-Joelsson BM, Kjellman B, Hattevig G: Tongue necrosis due to vasculitis. Acta Paediatr 1995, 84:1333-1336.
37. Grishman E, Spiera H: Vasculitis in connective tissue diseases, including hypocomplementemic vasculitis. In Systemic Vasculitides Edited by Churg A, Churg J. New York: Igaku-Shoin; 1991:273-292.
38. Wallace MR, Garst PD, Papadimos TJ, Oldfield EC: The return of acute rheumatic fever in young adults. JAMA 1989, 262:2557-2561.
39. Morris K, Mohan C, Wahi PL, Anand IS, Ganguly NK: Increase in activated T cells and reduction in suppressor/cytotoxic T cells in acute rheumatic fever and active rheumatic disease: a longitudinal study. J Infect Dis 1993, 167:979-983.
40. Pruksakorn S, Currie B, Brandt E, Phomphutkul C, Hunsakunachai S, Manmontri A, et al: Identification of T-cell autoepitopes that cross-react with the C-terminal segment of the M protein of group A streptococci. Int Immunol 1994, 6:1235-1244.
41. Watanabe-Ohnishi R, Aelion JA, LeGros HL, Tomai MA, Sokurenko EV, Newton D, et al: Characterization of unique human TCR Vβ specificities for a family of streptococcal superantigens represented by rheumatogenic serotypes of M protein. J Immunol 1994, 152:2066-2073.
42. Abbott WGH, Skinner MA, Voss L, Lennon D, Tan PLJ, Fraser JD, et al: Repertoire of transcribed peripheral blood T-cell-receptor beta chain variable-region genes in acute rheumatic fever. Infect Immun 1996, 64:2842-2845.
43. Garrett PJ, Bass PS, Atchley JT, Theaker JM, Dathan JR: Wegener's granulomatosis and acute poststreptococcal glomerulonephritis. Nephrol Dial Transplant 1993, 8:454-455.
44. Rovan RD, Zawada ET, Santella RN, Jaqua RA: Cerebral vasculitis associated with acute post-streptococcal glomerulonephritis. Am J Nephrol 1997, 17:89-92.
45. Poon-King R, Bannan J, Viteri A, Cu G, Zabriskie JB: Identification of an extracellular plasmin binding protein from nephritogenic streptococci. J Exp Med 1993, 178:759-763.
46. Cu GA, Mezzano S, Zabriskie JB: Role of streptococcal proteinase in acute post-streptococcal glomerulonephritis. Adv Exp Med Biol 1997, 418:137-140.
47. Vogt A, Batsford S, Rodriques-Iturbe B, Garcia R: Cationic antigens in poststreptococcal glomerulonephritis. Clin Nephrol 1983, 6:271-279.
48. Abe J, Forrester J, Nakahara T, Lafferty JA, Kotzin BL, Leung DYM: Selective stimulation of human T cells with streptococcal erythrogenic toxins A and B. J Immunol 1991, 146:3747-3750.
49. Parra G, Platt JL, Falk RJ, Rodriquez-Iturbe B, Michael AF: Cell populations and membrane attack complex in glomeruli of patients with post-streptococcal glomerulonephritis: identification using monoclonal antibodies by indirect immunofluorescence. Clin Immunol Immunopathol 1984, 33:324-332.
50. Koyama A, Kobayashi M, Yamaguchi N, Yamagata K, Takano K, Nakajima M, et al: Glomerulonephritis associated with MRSA infection: a possible role for bacterial superantigen. Kidney Int 1995, 47:207-216.
51. Kobayashi M, Yoh K, Iwabuchi S, Muro K, Kondoh M, Yamamoto M, et al: Lymphocyte subsets in glomerulonephritis associated with MRSA infection. J Am Soc Nephrol 1996, 7:1776.
52. + T cells was increased but decreased in parallel with clinical recovery.
53. Gribetz D, Landing BH, Larson EL: Kawasaki disease: mucocutaneous lymph node syndrome (MCLS). In Systemic Vasculitides. Edited by Churg A, Churg J. New York: Igaku-Shoin; 1991:257-272.
54. Leung DYM: Kawasaki disease. Curr Opin Rhematol 1993, 5:41-50.
55. Leung DYM, Geha RS, Newburger JW, Burns JC, Fiers W, Lapierre LA, Pober JS: Two monokines, IL-1 and TNF, render cultured vascular endothelial cells susceptible to lysis by antibodies circulating during Kawasaki syndrome. J Exp Med 1986, 164:1958-1972.
56. Leung DYM, Siegel RL, Grady S, Krensky A, Meade R, Reinherz EL, Geha RS: Immunoregulatory abnormalities in mucocutaneous lymph node syndrome Clin Immunol Immunopathol 1982, 23:100-112.
57. Barron K, DeCunto C, Montalvo J, Orson F, Lewis D: Abnormalities of immunoregulation in Kawasaki syndrome. J Rheumatol 1988, 15:1243-1249.
58. Pietra BA, De Inocencio J, Giannini EH, Hirsch R: TCR VB family repertoire and T cell activation markers In Kawasaki disease. J Immunol 1994, 153:1881-1888.
59. + T cells in Kawasaki disease. J Immunol 1997, 159:481-486.
60. Leung DYM, Meissner HC, Fulton DR, Murray DL, Kotzin BL, Schlievert PM. Toxic shock syndrome toxin-secreting Staphylococcus aureus in Kawasaki syndrome Lancet 1993, 342:1385-1388.
61. Leung DYM, Meissner HC, Schlievert PM: The etiology and pathogenesis •• of Kawasaki disease-how close are we to an answer? Curr Opin Infect Dis 1997, 10:226-232. This is an excellent review on the cause and pathogenesis of KD with special attention to the possible pathophysiologic role of SAgs
62. Deresiewicz RL, Flaxenburg J, Leng K, Kasper DL: Sequence of the toxic shock syndrome toxin gen (tstH) borne by strains of Staphylococcus aureus isolated from patients with Kawasaki syndrome. Infect Immun 1996, 64:3394-3396.
63. Curtis N, Chan B, Levin M: Toxic shock syndrome toxin-secreting Staphylococcus aureus in Kawasaki syndrome. Lancet 1994, 343:299-300.
64. Terai M, Miwa K, Williams T, Kabat W, Fukuyama M, Okajima Y, et al: The absence of evidence of staphylococcal toxin involvement in the pathogenesis of Kawasaki disease. J Infect Dis 1995, 172:558-561.
65. Todome Y, Ohkuni H, Mizuse M, Okibayashi F, Ohtani N, Susuki H, et al. Superantigenic exotoxin production by isolates of Staphylococcus aureus from the Kawasaki syndrome patients and age-matched control children. J Med Microbiol 1995, 42:91-95.
66. Abe J, Kotzin BL, Jujo F, Melish ME, Glode MP, Kohsaka T, Leung DYM: Selective expansion of T cells expressing T-cell receptor variable regions VB2 and VB8 in Kawasaki disease. Proc Natl Acad Sci U S A 1992, 89:4066-4070.
67. Abe J, Kotzin BL, Messner C, Melish ME, Takahashi M, Fulton D, et al: Characterization of T cell repertoire changes in acute Kawasaki disease. J Exp Med 1993, 177:791-796.
68. Curtis N, Zheng R, Lamb JR, Levin M: Evidence for a superantigen mediated process in Kawasaki disease. Arch Dis Child 1995, 72:308-311.
69. + T helper cells. Clin Exp Immunol 1995, 99:276-282.
70. + T cells in the small intestinal mucosa in Kawasaki disease. Pediatr Res 1996, 39:264-266.
71. Jason J, Montana E, Donald JF, Seidman M, Inge KL, Campbell R: Kawasaki disease and T-cell antigen receptor. Hum Immunol 1998, 59:29-38.
72. + T cells, which decreased toward normal during treatment.
73. Leung DYM, Giorno RC, Kazemi LV, Flynn PA, Busse JB: Evidence for superantigen involvement in cardiovascular injury due to Kawasaki syndrome. J Immunol 1995, 155:5018-5021.
74. Stegeman CA, Cohen Tervaert JW: Contemporary diagnosis and manage• ment of Wegener's granulomatosis. Curr Opin Otolaryngol Head Neck Surg 1997, 5:181-186. This review focuses on the current possibilities for diagnosing and treating patients with WG
75. + T-cell subsets in Wegener's granulomatosis. Rheumatol Int 1995, 14:213-219.
76. Giscombe R, Grunewald J, Nityanand S, Lefvert AK: T cell receptor (TCR) V gene usage in patients with systemic necrotizing vasculitis. Clin Exp Immunol 1995, 101:213-219.
77. Popa ER, Stegeman CA, Bos NA, Kallenberg CGM, Cohen Tervaert JW: T-lymphocyte but not B-lymphocyte activation in Wegener's granulomatosis persists during remission. J Am Soc Nephrol 1997, 8:543A.
78. Muller Kobold AC, Kallenberg CGM, Cohen Tervaert JW: Monocyte activation in patients with Wegener's granulomatosis Ann Rheum Dis, in press.
79. Stegeman CA, Cohen Tervaert JW, Manson WL, Sluiter WJ, de Jong PE, Kallenberg CGM: Chronic nasal carriage of Staphylococcus aureus in Wegener's granulomatosis identifies a subgroup of patients more prone to relapses. Ann Intern Med 1994, 120:12-17.
80. Reinhold-Keller E, de Groot K, Rudert H, Nölle B, Heller M, Gross WL: Response to trimethoprim/sulfamethoxazole in Wegener's granulomatosis depends on the phase of disease. QJM 1996, 89:15-23.
81. Stegeman CA, Cohen Tervaert JW, De Jong PE, Kallenberg CGM, for the Dutch Cotrimoxazole Study Group: Trimethoprim-sulfamethoxazole for the prevention of relapses of Wegener's granulomatosis. N Engl J Med 1996, 335:16-20.
82. Cohen Tervaert JW, Stegeman CA, Bakker H, Arends J, Manson WL, Kallenberg CGM: Staphylococcus aureus in Wegener's granulomatosis: a role for toxic shock syndrome toxin-1 (TSST-1) production? J Am Soc Nephrol 1995, 6:920.
83. Cohen Tervaert JW, Stegeman CA, Manson WL, Kallenberg CGM, Johnson WM: Staphylococcus aureus superantigens: a risk factor for disease reactivation in Wegener's granulomatosis. FASEB J 1998, 12-A488
84. Popa ER, Stegeman CA, Bos NA, Kallenberg CGM. Cohen Tervaert JW: T-cell activation and TCR Vβ skewing in Wegener's granulomatosis: indicators for superantigenic activation? Clin Exp Immunol 1998, 112(suppl 1):16.
85. Simpson IJ, Skinner MA, Geursen A, Peake JS, Abbott WG, Fraser JD, et al: Peripheral blood T lymphocytes in systemic vasculitis: increased T cell receptor Vβ2 gene usage in microscopic polyarteritis Clin Exp Immunol 1995, 101:220-226.
86. Fast DJ, Schlievert PM, Nelson RD: Toxic shock syndrome-associated staphylococcal and streptococcal pyrogenic toxins are potent inducers of tumor necrosis factor production. Infect Immun 1989, 57:291-296.
87. Andersson R, Hansson GK, Soderstrom T, Jonsson R, Bengtsson BA, Nordborg E: HLA-DR expression in the vascular lesion and circulating T lymphocytes of patients with giant cell arteritis. Clin Exp Immunol 1988, 73:82-37.
88. + T cell expansions using selected TCR V and J gene segments at the onset of giant cell arteritis. Arthritis Rheum 1994, 37:1221-1227.
89. Seko Y, Minota S, Kawasaki A, Shinkai Y, Maeda K, Yagita H, et al: Perforin-secreting killer cell infiltration and expression of a 65-kD heat-shock protein in aortic tissue of patients with Takayasu's arteritis. J Clin Invest 1994, 93:750-758.
90. Nityanand S, Giscombe R, Srivastava S, Hjelmstrom P, Sanjeevi CB, Sinha • N, et al: A bias in the aβ T cell receptor variable region gene usage in Takayasu's arteritis. Clin Exp Immunol 1997, 107:261-268. To elucidate the role of T cells in patients with Takayasu's arteritis, circulating T cells of 18 Indian patients were studied. Patients had a higher percentage of activated circulating T cells and TCR Vβ expansions compared with age-matched controls.
91. Sekiguchi M, Susuki J An overview on Takayasu arteritis. Heart Vessels 1992, 7:6-10.
92. Arbiser JL, Dzieczkowski JS, Harmon JV, Duncan LM: Leukocytoclastic vasculitis following staphylococcal protein A column immunoadsorption therapy: two cases and a review of the literature. Arch Dermatol 1995, 131 707-709.